Tag: GlobeNewswire

New Energy Group EPSO-G (legal entity code 302826889, registered office address Laisvės pr. 10, Vilnius, Lithuania)

EPSO-G Invest, the EPSO-G group’s company managing investments in the defence industry, announces a public selection process for the position of CEO. Applications for this position may be submitted until 03-12-2026 inclusive.

In line with the highest standards of transparency and good governance practices, representatives of both shareholders of EPSO-G Invest will participate in the candidate selection process: the EPSO-G Remuneration and Nomination Committee, in which independent members form the majority, and a representative of Valstybės investicinis kapitalas. The selection process will be conducted by the recruitment agency AIMS International Lietuva.

Once the selection procedures have been completed and the candidates have been vetted in accordance with the requirements of the Law on the Protection of Objects of Importance to Ensuring National Security and the Law on the Prevention of Corruption, the decision on the appointment of the CEO from among the selected candidates will be made by the general meeting of shareholders of EPSO-G Invest.

EPSO-G Invest is a company of the new energy group EPSO-G, 51% of whose shares are held by EPSO-G and the remaining 49% by Valstybės investicinis kapitalas.

The requirements for candidates and the application procedure can be found here: EPSO-G-Invest-vadoves-o-skelbimas_2026-11-03.pdf

The EPSO-G group of companies consists of the holding company EPSO-G and its six direct subsidiaries Amber Grid, Baltpool, Energy cells, EPSO-G Invest, Litgrid and Tetas. EPSO-G and its Group companies also hold shares in Rheinmetall Defence Lietuva, Baltic RCC OÜ and TSO Holding AS. The rights and obligations of the sole shareholder of EPSO-G are exercised by the Ministry of Energy of the Republic of Lithuania.

The retail turnover (including VAT) of the Apranga Group amounted to EUR 36.1 million in October 2026 and increased by 4.1% compared to October 2025.

The retail turnover (including VAT) of Apranga Group reached EUR 326.9 million in January-October 2026 and increased by 8.8% compared to the corresponding period of 2025.

In January-October 2026, the retail turnover of Apranga Group in Lithuania increased by 10.6% year-to-year, in Latvia increased by 5.9% and increased by 6.4% in Estonia.

Currently Apranga Group operates the chain of 174 stores (103 in Lithuania, 44 in Latvia, and 27 in Estonia) with a total area of 93.7 thousand sq. m., or by 1.1% more than a year ago.

Rimantas Perveneckas
„Apranga“ Group General Manager
+370 5 2390801

– Company to Host Conference Call on November 10, 2026, at 4:30 p.m. ET –

SAN DIEGO, Nov. 03, 2026 (GLOBE NEWSWIRE) — Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced that it will release its financial results for the third quarter ended September 30, 2026, after the market close on Tuesday, November 10, 2026. Management will host a conference call and webcast at 4:30 p.m. ET that same day.

Title:	Capricor Therapeutics Third Quarter 2026 Financial Results and Recent Corporate Update Conference Call and Webcast
Date:	Tuesday, November 10, 2026
Time:	4:30 p.m. ET
Call Details:	Toll-Free: 1-800-717-1738
	International: 1-646-307-1865
	Conference ID: 13662
	Participants may dial in using the numbers above and ask to be joined to the call, or use the Call me™ link for instant telephone access to the event.
Webcast:	Click here

A replay of the webcast will be available shortly after the conclusion of the live event and will be accessible in the Investors section of the Company’s website at www.capricor.com.

About Capricor Therapeutics

Capricor Therapeutics (NASDAQ: CAPR) is a biotechnology company dedicated to advancing cell and exosome-based therapeutics for the treatment of rare diseases. Our lead product candidate, Deramiocel, is an allogeneic cardiac-derived cell therapy in late-stage development for the treatment of Duchenne muscular dystrophy (DMD), evaluated in clinical studies for its potential to preserve skeletal and cardiac muscle function. Capricor is also advancing its proprietary StealthX™ exosome platform for the targeted delivery of oligonucleotides, proteins, and small-molecule therapeutics across a range of diseases. At Capricor, we are committed to delivering new therapies for patients with rare diseases. For more information, visit capricor.com and follow Capricor on Facebook, Instagram and X.

Cautionary Note Regarding Forward-Looking Statements

Statements in this press release regarding the efficacy, safety, and intended utilization of Capricor’s product candidates; the initiation, conduct, size, timing and results of clinical trials; the pace of enrollment of clinical trials; plans regarding regulatory filings, future research and clinical trials; regulatory developments involving products, including future interactions with regulatory authorities and the ability to obtain regulatory approvals or otherwise bring products to market; manufacturing capabilities; dates for regulatory meetings; the potential that required regulatory inspections may be delayed or not be successful, which would delay or prevent product approval; revenue and reimbursement estimates; projected terms of definitive agreements, our financial position, our possible uses of existing cash and investment resources; results of securities litigation; and statements regarding our litigation with Nippon Shinyaku Co., Ltd. and NS Pharma, Inc., including the nature of the dispute, our expectations regarding any legal proceedings, and our ability to commercialize Deramiocel independent of our existing distribution agreement and any other statements about Capricor’s management team’s future expectations, beliefs, goals, plans or prospects constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words “believes,” “plans,” “could,” “anticipates,” “expects,” “estimates,” “should,” “target,” “will,” “would” and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements. More information about these and other risks that may impact Capricor’s business is set forth in Capricor’s Annual Report on Form 10-K for the year ended December 31, 2025, as filed with the Securities and Exchange Commission on March 17, 2026 and in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, as filed with the Securities and Exchange Commission on August 14, 2026. All forward-looking statements in this press release are based on information available to Capricor as of the date hereof, and Capricor assumes no obligation to update these forward-looking statements.

Deramiocel and Capricor’s StealthX™ exosome therapeutics are investigational and have not been approved for commercial use in any indication.

For more information, please contact:

Capricor Media Contact:
Caitlin Kasunich / Raquel Cona
KCSA Strategic Communications
ckasunich@kcsa.com / rcona@kcsa.com
212.896.1241 / 516.779.2630

Capricor Company Contact:
AJ Bergmann, Chief Financial Officer
abergmann@capricor.com
858.727.1755

Following a court-supervised restoration, NUGS plans to combine with Scopien, a sovereign AI platform

LOS ANGELES, Nov. 03, 2026 (GLOBE NEWSWIRE) — Cannabis Strategic Ventures, Inc. (OTC: NUGS) (“NUGS” or the “Company”) today announced that it signed a binding letter of intent (the “LOI”) with Scopien Technologies Inc. (“Scopien”), an Ontario corporation. Under the LOI, Scopien would acquire voting control of NUGS through the transfer of the Company’s Series B Super Voting Preferred Stock and contribute its operating business to the Company. The parties intend to complete the change of control by November 30, 2026.

Termination of Adport Letter of Intent

The Company also announced that it has terminated the non-binding letter of intent with Adport Inc. announced on September 10, 2026, under which the Company had proposed to acquire substantially all of Adport’s intellectual property and operating assets. No definitive agreements were entered into with Adport.

About the Scopien Platform

Scopien connects a company’s systems, including CRM, ERP, HR, payroll and helpdesk, into one operating platform and puts AI agents to work across it. Each customer runs its own instance in Scopien’s cloud, its own cloud or on-premises, so data stays inside its walls. Scopien serves mid-market companies, enterprises and government, and plans to expand its sales and partner channels, product modules and engineering program.

What Comes Next

When the change of control closes, Scopien would appoint NUGS’s officers and directors. The Company intends to change its name and trading symbol to reflect the Scopien business, subject to FINRA processing, and to complete PCAOB audits and file a registration statement with the SEC within six months following the change of control, with the goal of becoming a fully reporting company and pursuing a Nasdaq or NYSE listing.

“We rebuilt this company through the courts so shareholders would have something real to build on,” said Richard C. Hawkins, Chief Executive Officer of NUGS. “Scopien is the kind of company we hoped to find.”

“Every business should work as one,” said Zameer Mulla, Chief Executive Officer of Scopien. “Being a public company holds us to the standard of transparency our customers expect. Our first priority is completing the audit and the registration statement.”

Court Custodianship

In July 2025, the Eighth Judicial District Court of Nevada, Clark County, appointed a custodian for the Company, which at the time had no operations and carried more than $14.6 million in legacy liabilities. The custodian reinstated the Company, ran a court-supervised creditor-notice process and, in December 2025, obtained an order barring unasserted claims. In April 2026, the Court ratified the custodian’s actions and returned control to the board. Total reported liabilities were approximately $491,000 at September 30, 2026, and all legacy Series C Preferred Stock has been cancelled.

About Scopien Technologies Inc.

Scopien Technologies Inc., based in Oakville, Ontario, builds sovereign AI that makes every business work as one. For more information, visit www.scopien.com.

About Cannabis Strategic Ventures, Inc.

Cannabis Strategic Ventures, Inc. is a Nevada corporation quoted on OTC Markets under the symbol “NUGS.” Following a court-supervised custodianship completed in April 2026, the Company is pursuing business combinations with operating businesses that have growth potential.

Investor Contact

info@cannabisstrategic.ventures | +1 480-788-7420

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements, including statements regarding the proposed change of control, the contribution of Scopien’s business, the audit and registration statement, and potential exchange listing. These statements are subject to significant risks and uncertainties, including: that definitive agreements may not be executed or the LOI may be terminated; that the audit and registration statement may not be completed as contemplated; that Scopien’s business may not grow as anticipated; that additional funding may not be available; that securities remain subject to former-shell-company resale restrictions under Rule 144(i); that exchange listing standards may not be met; and that legacy indebtedness and future financing may substantially dilute common stockholders. The super-voting preferred stock would concentrate voting control in Scopien.

The safe harbor provided by Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 is not available to the Company. The Company undertakes no obligation to update any forward-looking statement except as required by law. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Source: Cannabis Strategic Ventures, Inc.

DALIAN, China, Nov. 03, 2026 (GLOBE NEWSWIRE) — CBAK Energy Technology Limited (NASDAQ: CBAT) (“CBAK Energy” or the “Company”), a China-based lithium-ion battery manufacturer and energy solutions provider, today reported that a battery pack manufacturer serving the automated guided vehicle (“AGV”) market has placed orders totaling approximately US$8.22 million, including applicable taxes, since their commercial relationship began in 2022. Initial battery cell evaluations took place in 2021. The customer purchases CBAK Energy’s 26650 PFS2 and 32140 FS full-tab cylindrical lithium iron phosphate (“LFP”) cells for AGV battery packs. AGVs are mobile robots that transport materials in warehouses and manufacturing facilities.

The Power Demands of AGVs

AGVs often operate across extended shifts with frequent starts, stops and changing loads. These conditions require consistent power delivery, while short charging windows make fast recharging important for reducing downtime. Limited battery space also places demands on pack design and thermal management. Battery pack manufacturers must balance power, charging speed, cycle life and space requirements for each application.

LFP Cells for AGV Battery Packs

For compact warehouse AGVs that move and recharge frequently, CBAK Energy’s 26650 PFS2 full-tab cylindrical LFP cell offers high-rate charging and discharging and achieved a cycle life of 3,000 cycles in Company testing. Its full-tab design helps reduce internal resistance and heat generation during high-current operation. The smaller cylindrical format also gives battery pack manufacturers flexibility when fitting cells into limited space.

For AGVs with higher energy requirements, the Company offers its 32140 FS large cylindrical LFP cell. In Company testing, the cell’s internal resistance was 1.3 mΩ, approximately 18% lower than that of comparable cells tested. It supports 2C fast charging and reached a full charge in approximately 30 minutes under specified test conditions. Its larger format can help reduce the number of cells needed for a battery pack, depending on the required energy capacity and pack design. These features make it an option for AGVs operating on longer routes, carrying heavier loads or working with short charging windows.

Customer Qualification and Ongoing Supply

CBAK Energy’s 26- and 32-series cylindrical LFP cells have passed the customer’s initial safety and performance evaluations. The Company draws on more than two decades of battery manufacturing experience, established quality controls and production capacity in Nanjing and Dalian to support ongoing supply. Its product testing and compliance practices address applicable UL safety standards, UN 38.3 transport testing and RoHS restrictions on hazardous substances. These capabilities support the customer’s qualification process and development of battery packs for different AGV applications.

“AGV applications are an important market for our cylindrical LFP cells,” said Zhiguang Hu, Chief Executive Officer of CBAK Energy. “Our relationship with this customer has grown from initial evaluations into several years of supply. It shows the commercial value of meeting demanding operating requirements while maintaining consistent product quality. Battery pack manufacturers need both suitable cells and a dependable supplier as their applications evolve. We intend to build on this experience to develop our product range and win more business in warehouse, logistics and manufacturing automation.”

About CBAK Energy

CBAK Energy Technology Limited (NASDAQ: CBAT) is a China-based company that develops, manufactures and sells high-power lithium-ion and sodium-ion batteries, as well as materials used in high-power lithium-ion batteries. It has battery cell production, research and development, and sales operations in Nanjing, Dalian and Shangqiu, with research and development centers in Nanjing and Dalian. Its raw materials business is based in Shaoxing. The Company’s products serve electric vehicles, light electric vehicles, energy storage systems and other high-power applications. In January 2006, CBAK Energy became the first Chinese lithium battery manufacturer to be listed on the Nasdaq Stock Market.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements include expectations regarding the continued development of the Company’s relationship with its AGV battery pack customer; order fulfillment, future customer demand, product qualification and supply opportunities; the suitability and expected performance of its cylindrical LFP cells in AGV applications; the potential benefits of cell design, fast charging, high-rate discharge and cycle life; the Company’s ability to maintain product quality and reliable supply; and its plans to develop its product range and expand its business in warehouse, logistics and manufacturing automation.

Words such as “expect,” “estimate,” “anticipate,” “believe,” “intend,” “plan,” “target,” “may,” “will,” “would” and “could,” and similar expressions, identify forward-looking statements. These statements are based on current expectations and assumptions and involve risks and uncertainties that could cause actual results to differ materially.

Risks include changes in customer demand, AGV market conditions and product requirements; the timing of order fulfillment and delivery; the outcome of customer testing and qualification; whether existing relationships lead to additional orders or expanded supply; differences between cell test results and actual battery pack or AGV performance; variations in charging time, cycle life and internal resistance under different conditions; manufacturing yields, product quality, production capacity and supply availability; battery pack design and charging strategies; applicable safety, certification, transportation and environmental requirements; competing battery technologies; and other risks described in the Company’s reports filed with or furnished to the U.S. Securities and Exchange Commission.

The cell performance figures in this release were obtained in Company testing under specified conditions. The comparative result applies to the cells tested. Actual battery pack and AGV performance, including charging time and cycle life, will depend on pack design, charging protocols, operating conditions, usage patterns and other factors.

Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Except as required by applicable law, the Company undertakes no obligation to update or revise any forward-looking statements as a result of new information, future events or otherwise.

For more information, please visit: https://en.cbak.com.cn/
Email: marketing@cbak.com.cn
LinkedIn: https://www.linkedin.com/company/cbakenergy
X: https://x.com/CBAKEnergy
Stocktwits: https://stocktwits.com/CBAK_Energy
Investor Relations
Email: ir@cbak.com.cn
Website: https://ir.cbak.com.cn/

Marcela Ronquillo Hinojosa to Support Strategic Partnerships, Financing Opportunities and Development of Hydrogen and CNG Infrastructure

Dallas, TX, Nov. 03, 2026 (GLOBE NEWSWIRE) — Vivakor, Inc. (Nasdaq: VIVK) (“Vivakor” or the “Company”), an integrated provider of energy transportation, storage, reuse and remediation services, today announced the engagement of international business strategist Marcela Ronquillo Hinojosa as a strategic consultant to support the development of the Company’s proposed hydrogen and compressed natural gas (“CNG”) infrastructure project at a major international airport in Texas.

The engagement follows Vivakor’s recent announcement of a nonbinding letter of intent to pursue a long-term lease of approximately 12.9 acres at the airport for the development of hydrogen and CNG fueling infrastructure, with potential future expansion into hydrogen production using airport-generated organic waste.

Ms. Ronquillo Hinojosa brings more than 20 years of experience in international business development, strategic partnerships and sustainable infrastructure. In her consulting role, she is expected to assist Vivakor in developing strategic relationships, identifying prospective financing opportunities and coordinating partnerships to support the advancement of the proposed airport project.

“Developing a project of this scale requires strong strategic partnerships and access to capital,” said James Ballengee, Chairman, President and Chief Executive Officer of Vivakor. “Marcela brings extensive international relationships and experience connecting businesses, financial institutions and government stakeholders. We believe her involvement will help us establish the commercial and financial relationships necessary to move this initiative forward.”

Ms. Ronquillo Hinojosa is the Founder and Chief Executive Officer of NewSpace Capital LLC, which develops and structures sustainable infrastructure initiatives, and Earth Carbon LLC, which focuses on ecosystem conservation and carbon market development. She also serves as Vice President of COMENER, the Mexican Energy Council, and previously served as Executive Director of EarthX Latin America, where she facilitated collaboration among corporations, governments and international organizations on sustainability initiatives.

“Vivakor’s proposed airport energy infrastructure project presents an exciting opportunity to bring together sustainable energy solutions and strategic investment,” said Ms. Ronquillo Hinojosa. “I look forward to leveraging my relationships and experience to help establish partnerships, identify financing opportunities and support the long-term success of this initiative.”

About Vivakor, Inc.

Vivakor, Inc. is an integrated provider of sustainable energy transportation, storage, reuse, and remediation services. Its corporate mission is to develop, acquire, accumulate, and operate assets, properties, and technologies in the energy sector. Vivakor’s integrated facilities assets provide crude oil, storage, transportation, reuse, and remediation services under long-term contracts. Once operational, Vivakor’s interest in oilfield waste remediation facilities will facilitate the recovery, reuse, and disposal of petroleum byproducts and oilfield waste products.

For more information, please visit our website: http://vivakor.co

Cautionary Statement Regarding Forward-Looking Statements
This news release may contain forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are based upon the current beliefs and expectations of our management and are inherently subject to significant business, economic and competitive uncertainties and contingencies, many of which are difficult to predict and generally beyond our control. Actual results and the timing of events may differ materially from the results anticipated in these forward-looking statements. Forward-looking statements may be identified but not limited by the use of the words “anticipates,” “expects,” “intends,” “plans,” “should,” “could,” “would,” “may,” “will,” “believes,” “estimates,” “potential,” or “continue” and variations or similar expressions. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including, but not limited to, the expected transaction and ownership structure, the valuation of the transaction, the likelihood and ability of the parties to successfully and timely consummate planned acquisitions, the risk that any required regulatory approvals are not obtained, are delayed or are subject to unanticipated conditions that could adversely affect Vivakor or the expected benefits of the such transaction, our ability to maintain the listing of our securities on The Nasdaq Capital Market, the parties failure to realize the anticipated benefits of pending transactions, disruption and volatility in the global currency, capital, and credit markets, changes in federal, local and foreign governmental regulation, changes in tax laws and liabilities, tariffs, legal, regulatory, political and economic risks, our ability to successfully develop products, rapid change in our markets, changes in demand for our future products, and general economic conditions.

These risks and uncertainties include, but are not limited to, risks and uncertainties discussed in Vivakor’s filings with the U.S. Securities and Exchange Commission, which factors may be incorporated herein by reference. Actual results, performance or achievements may differ materially, and potentially adversely, from any projections and forward-looking statements and the assumptions on which those forward-looking statements are based. There can be no assurance that the data contained herein is reflective of future performance to any degree. You are cautioned not to place undue reliance on forward-looking statements as a predictor of future performance as projected financial information and other information are based on estimates and assumptions that are inherently subject to various significant risks, uncertainties and other factors, many of which are beyond our control. All information set forth herein speaks only as of the date hereof in the case of information about Vivakor or the date of such information in the case of information from persons other than Vivakor, and we disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this communication. Forecasts and estimates regarding the industries and markets are based on sources we believe to be reliable; however, there can be no assurance these forecasts and estimates will prove accurate in whole or in part.

Investor Contact:
P:469-480-7175
info@vivakor.com

Company’s first in-booth press conference Nov. 3 will highlight new products across four consumer verticals, its strategic collaboration with Amotiv, and the SXTH Element acquisition

NASHVILLE, Tenn., Nov. 03, 2026 (GLOBE NEWSWIRE) — Holley Performance Brands (NYSE: HLLY), home to a portfolio of iconic automotive brands serving enthusiasts across the high-performance aftermarket, today announced its plans for the 2026 SEMA Show, Nov. 3–6 at the Las Vegas Convention Center. In Central Hall Booth #22463, Holley will host its first-ever in-booth press conference on Tuesday, Nov. 3, at noon PST, where leaders from American Performance, Modern Truck & Off-Road, Safety & Racing, and Euro & Import will introduce new products and highlight five builds and displays featuring brands from across Holley’s portfolio.

Holley’s SEMA presence follows its Oct. 29 acquisition of SXTH Element and Oct. 26 announcement of a strategic collaboration with Amotiv Limited (ASX: AOV). Both will be highlighted in the booth alongside new product launches from AEM and Edge. Holley will also meet with its top distribution partners during SEMA week to align on priorities and opportunities for 2027.

“SEMA provides an important platform to demonstrate the strength of our brands, the innovation taking place across our business and the partnerships helping us expand our reach,” said Matthew Stevenson, President and Chief Executive Officer of Holley Performance Brands. “Our focus remains on delivering meaningful product innovation, connecting with enthusiasts and creating new opportunities across the automotive aftermarket. This year’s show reflects the breadth of our portfolio and the work our teams are doing to position Holley for long-term success.”

What Holley will show at SEMA 2026

• American Performance – Product highlights include the AEM X-Series Plus wideband air-fuel ratio gauge, which adds smart warm-up sensor protection and OBD connectivity for compatible 2008-and-newer vehicles. The division will also feature Holley High-Performance Car Care, developed with Malco Automotive and launched in April. The featured build is “Cream Soda,” a 1993 Chevrolet S10 built by content creator Justin Nunley and Emerald Coast Classics around a 6.0-liter LQ9 engine. It runs Holley Terminator X Max EFI, a 12.3-inch Pro Dash, a Level Four LS Swap Essentials package, NOS nitrous, MSD ignition, Earl’s plumbing and Baer Pro+ brakes.
• Modern Truck & Off-Road – The Edge CTS4 lineup will make its SEMA debut, including Insight, Insight+, Evolution and Juice with Attitude, built around a 5.5-inch display for live data, custom gauges, diagnostics and alerts. The division will also show Range DFM Pro for supported GM trucks and SUVs, along with Edge EZ for 2025-and-newer Ram Cummins trucks. Two builds anchor the display: a 2025 Ford F-150 regular cab customized by Waldoch with Edge Insight CTS4, Flowmaster exhaust, Baer brakes, NOS nitrous and Amp’d throttle enhancement, alongside SXTH Element’s 2024 Toyota Tacoma.
• Euro & Import – APR will show its Stage 3+ turbo program for the Volkswagen Golf R and GTI, along with PDK2 transmission tuning for the Porsche 992.1. Dinan will feature its M-Hunter package for BMW M40i models. The featured build is an Alpine White 2026 BMW M3 Competition equipped with a Dinan carbon-fiber intake, PCU, valved exhaust and adjustable coilovers. Dinan prototypes will also be on display. Together, these products highlight Holley’s combination of software tuning and performance hardware across Volkswagen, Porsche, and BMW platforms.
• Safety & Racing – SEMA attendees will get an early look at products launching at PRI, including Simpson’s refreshed racewear line (Standard Titanium, Sportsman Titanium and SLT-II suits), the Simpson Devil Ray 4 helmet built on the Snell SA2025 platform, HRX’s North American lineup, Stilo WRX helmets and Simpson’s updated harness line. The featured display is a drag racing cockpit built by M&M Race Cars with a Simpson seat, D3 harness and parachute system.

Holley Performance Brands brings major announcements & automotive icons to the SEMA Show.

SXTH Element joins Holley’s Modern Truck & Off-Road vertical, expanding its offering for late-model Toyota trucks and SUVs. Based in Spartanburg, S.C., the brand designs and engineers cold-air intakes, intercoolers, charge pipes, turbo inlets and catch cans, with applications across the Tacoma, 4Runner, Tundra, Sequoia and Land Cruiser. Its airflow and forced-induction products complement Holley’s existing tuning and exhaust capabilities, creating opportunities to offer more complete performance solutions for these platforms over time. Holley also plans to expand SXTH Element’s availability through its network of B2B partners.

Holley will also highlight its strategic collaboration with Amotiv, combining Holley’s enthusiast brands and established North American customer channels with Amotiv’s aftermarket brands, product expertise and technical capabilities. The first planned initiative is Flowmaster Engineered by Ryco Performance Oil Filters, a line for North America using Ryco’s race-inspired, award-winning SynTec technology. The initiative marks Flowmaster’s entry into filtration and supports Holley’s strategy of extending its brands into adjacent product categories. Holley and Amotiv will share further details during a joint segment of the press conference.

Holley continues to broaden where enthusiasts can find its products through expanded national retail distribution, putting popular products from across its portfolio in front of more customers.

To reach enthusiasts who can’t attend in person, Holley will extend its SEMA presence through original content, social media and creator collaborations. Booth appearances will include Tony Stewart, Leah Pruett and Matt Hagan of TSR Nitro; Stephan Papadakis and Fredric Aasbo; Bill Goldberg; and Stacey David, host of GearZ.

At the Nov. 3 press conference, Matthew Stevenson will be joined by Nick Hite, Senior Vice President, American Performance; Aaron Stewart, Senior Vice President, Modern Truck & Off-Road; Dan Waters, Senior Sales Director, Safety & Racing; Cristian Fernandez, Senior Director, European Performance; and Graeme Whickman, Managing Director and Chief Executive Officer of Amotiv Limited. Company leadership will be available for media interviews after the presentation.

For more Holley company news, click here.

Forward-Looking Statements
Certain statements in this press release may be considered “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Such forward-looking statements are subject to risks, uncertainties, and other important factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements, including but not limited to Holley’s ability to execute and successfully commercialize its planned new product launches, Holley’s ability to achieve the anticipated benefits expected from the collaboration with Amotiv, Holley’s ability to successfully integrate the SXTH Element business, grow the business and its product offering, or otherwise fully realize the expected benefits associated with its acquisition of SXTH Element, anticipated growth of the vehicle brands, makes and models that SXTH Element products support, and the other risks and uncertainties set forth in the Annual Report on Form 10-K for the year ended December 31, 2025 filed with the U.S. Securities and Exchange Commission (“SEC”) on March 16, 2026, and in any subsequent filings with the SEC.

About Holley Performance Brands
Holley Performance Brands (NYSE: HLLY) is home to a portfolio of iconic brands that serve enthusiasts across the high-performance aftermarket. The company designs, engineers, manufactures and markets category-leading products and solutions for automotive enthusiasts through a focused portfolio spanning four consumer vertical groupings: American Performance, Modern Truck & Off-Road, Euro & Import, and Safety & Racing. For more than a century, Holley has built its reputation through innovation, technical expertise and a deep understanding of enthusiast culture. For more information, visit holley.com.

Media Relations Contact(s):
Nathan Espinosa, Michael Murray
Kahn Media
818-881-5246
Holley@KahnMedia.com

Investor Relations Contact(s):
Sloan Bohlen, Jenna Kozlowski
Solebury Strategic Communications
203-428-3224
Holley@soleburystrat.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/cf62bae8-b2ae-4daa-8d03-2dcf41e96f3d

Former Source Electronics and Avnet executive Doug Adams joins CEO Bill Wentworth and VP Sales and Marketing Monty Reagan to lead Data I/O’s expansion into Programming-as-a-Service (PaaS) as the Company integrates recently acquired A&J Programming

REDMOND, Wash., Nov. 03, 2026 (GLOBE NEWSWIRE) — Data I/O Corporation (NASDAQ: DAIO), the leading global provider of data programming equipment, provisioning services and security provisioning for Flash-based microcontrollers, and high-density memory devices, today announced the appointment of Douglas Adams as SVP Global Services, Support and Quality.

The appointment reunites Mr. Adams with Data I/O President and CEO Bill Wentworth and Vice President of Sales and Marketing Monty Reagan. Together, these three key, senior executives led the growth of Source Electronics into the largest independent device programming services business in the world, founded by Mr. Wentworth in 1988, sold to HIG Capital in 2001 and then acquired in 2008 by Avnet Inc. “This executive team has well over 100 years of direct experience in device provisioning and has helped set industry best practices, guided by our corporate pillars of quality, execution, and industry-leading KPIs. Source Electronics became the largest provisioning services business worldwide,” said Bill Wentworth, CEO of Data I/O. “Together we are now pairing our services experience with the Data I/O brand, along with newly acquired V-TEK, Inc. and A&J Programming, Inc. to accelerate our services strategy. The acquisition diversifies our customer base, reducing our reliance on the automotive industry and adding new lines of revenue not related to capital expenditure cycles. There is significant revenue opportunity to unlock value within A&J’s existing customer base. A&J has built an outstanding reputation over the last several decades in Silicon Valley. With our new leadership team we will build on top of that value A&J has developed with focus and execution to align with customers’ supply chain needs.

“With Doug joining the team, Data I/O now brings the industry’s most recognized brand in programming solutions and the industry’s most proven programming services leadership team together under one roof. This combination forms the foundation for Data I/O’s entry into Programming-as-a-Service (PaaS) to deliver programming services regionally and globally. Doug has recently been a consultant for Data I/O preparing for the acquisition and connecting with team members. This preparation will allow us to get out of the gate quickly.”

The appointment of Doug Adams follows the completion of Data I/O’s October 21, 2026, transformational acquisition of V-TEK, Inc. and A&J Programming, Inc. (collectively, “V-TEK”), which is anticipated to double the Company’s revenue and expand Data I/O into new markets, including data centers, AI, photonics, industrial automation, medical, military, aerospace and defense. A&J’s service expertise gives Data I/O an established programming services operation and an experienced team, significantly accelerating the Company’s PaaS rollout. A&J Programming will continue to serve its customers as “A&J Programming, a Data I/O Company.”

Douglas Adams: Operational Leadership at Global Scale

Mr. Adams served as VP of Sales and Marketing for Source Electronics prior to becoming COO. Mr. Wentworth promoted Doug to Chief Operating Officer of Source Electronics after a partner buy-out, where Doug led the operations that made Source the largest independent programming services provider worldwide. After Source Electronics was acquired by Avnet, Messrs. Wentworth and Adams grew Avnet’s programming business by 50% in four years. In 2014, Mr. Wentworth left Avnet and Doug led global operations for logistics, programming services, and quality LPSQ worldwide. He oversaw operations of 13 global distribution centers, 8 regional programming centers and over 30 ISO 9001 quality certifications. During his tenure at Avnet, Mr. Adams expanded and led the build-out of programming services on a global scale, overseeing the opening of multiple new regional programming centers, while maintaining six sigma level quality and superior customer experience.

Entering PaaS – Onsite and Regional Programming Services

“We are not abandoning the capital equipment business in any way; quite the opposite. We are expanding the solutions available to all customers and supply chain partners,” said Mr. Wentworth. “Investments in the core business and striving to build the best solutions in the industry will benefit Data I/O’s current and future customers allowing them to buy both capital equipment and services. With A&J Programming now part of the NEW Data I/O, we have a programming services operation in place today, and Doug is the right leader to scale it, just as he did at Avnet. Growing software and services are a key part of our future growth plan. Customers will continue to have the option to purchase our programming solutions and deploy them in their factories and utilize our regional programming service centers to help manage peak demand spikes.”

“Programming services is an integral part of the customer’s supply chain. It is fundamentally an operations business: disciplined process control, quality focused, strong IT security, and centered around customer success,” said Doug Adams, SVP Global Services, Support and Quality of Data I/O. “Data I/O has the technology and the installed base to grow services from which customers can opt for an OpEx vs. CapEx. It’s simple: more options lead to more customer satisfaction.”

Mitch Jacobs, SVP of Manufacturing and former CEO of V-TEK, stated, “During my first trip with Doug to the A&J facility, it was immediately apparent his connection with the team and the excitement throughout the building. Doug’s knowledge of the services business and his reputation for driving disciplined execution and scaling operations to meet customers’ global requirements is precisely what we are all very excited about. A&J Programming gives us a strong starting point: an experienced team and a working services operation, backed by V-TEK’s handling and automation systems and Data I/O’s programming and security technology. Being able to provide our customers with this new option creates an environment where we can help our customers regarding supply chain or region.”

About Data I/O Corporation
Since 1972, Data I/O Corporation (NASDAQ: DAIO) has been the global leader in device programming. In 2026, Data I/O united three industry leaders with the transformational acquisition of V-TEK, Inc. and A&J Programming, Inc. The combination enables Data I/O to provide the world’s most comprehensive solutions to support the entire data provisioning supply chain.  These solutions include data programming and security provisioning, semiconductor handling automation for test, inspection and packaging, and Programming-as-a-Service. The Company serves customers in the automotive, industrial automation, data center, AI, photonics, medical, military, aerospace and defense, IoT, and consumer electronics markets. OEMs and manufacturers of any size can program, securely provision, test and package devices from early samples through high-volume production, using modular and customized systems and flexible service options. Data I/O’s solutions are backed by a portfolio of patents (dataio.com/Company/Patents) and a global network of distribution partners and support and service professionals, ensuring success for customers.

Learn more at www.dataio.com, www.vtekusa.com, and www.ajprogram.com.

Forward-Looking Statements

Safe Harbor/Forward Looking Statements and Disclosure Information
The Company cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements, including the benefits anticipated from the acquisition. Such forward-looking statements involve risks, assumptions and uncertainties. Statements in this news release may be construed as a prediction of future operations and performance or events are forward-looking statements which involve known and unknown risks, uncertainties and other factors which may cause actual results to differ materially from those expressed or implied by such statements.

Forward-looking statement disclaimers also apply to the timing and contributions of acquisitions, acquisition synergies, the demand for the Company’s products, the impact from geopolitical conditions including any related international trade restrictions, and cybersecurity incidents and the possibility that the Company’s containment and remediation efforts may be unsuccessful or becomes a challenging force in maintaining market share. Factors that may impact the Company’s operations and finances include uncertainties as to the ability to record revenues based upon the timing of product deliveries, market acceptance of Edge AI, shipping availability, installations and acceptance, accrual of expenses, coronavirus or other business interruptions, changes in economic conditions, part shortages, business disruptions and other risks including those described in the Company’s 10-K, 10-Q and other periodic filings with the Securities and Exchange Commission (SEC), press releases and other communications.

Data I/O may use its website (www.dataio.com) and investor relations page (www.dataio.com/Company/Investor-Relations), its X account (@DataIO_Company), and its LinkedIn page (linkedin.com/company/data-io) to disclose material non-public information and for complying with its disclosure obligations under Regulation FD. Accordingly, investors and other interested parties should monitor these sites, in addition to following Data I/O’s press releases, Securities and Exchange Commission (SEC) filings, public conference calls and public presentations/webcasts.

Media Contacts
Data I/O Corporation
Jennifer Higgins
Director Corporate Marketing
higginj@dataio.com

+1-425-867-6922

Investor Contact
Darrow Associates, Inc.
Jordan Darrow
jdarrow@darrowir.com
+1-631-766-4528

Earnings conference call to be held on November 13, 2026, at 8:30 a.m. Eastern Time

IRVINE, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) — SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“The Company” or “SBC Medical”), a Medical Services Organization (MSO) providing management support across a wide range of healthcare fields, today announced that it will release its financial results for the third quarter ended September 30, 2026, before U.S. market open on November 13, 2026.

Management will host an earnings conference call on November 13, 2026, at 8:30 a.m. Eastern Time. A question-and-answer session with investors and analysts will follow the prepared remarks.

Please register in advance for the conference using the link provided below.

[https://zoom.us/webinar/register/WN_CLFqOL3XTourhX2qjAJnxw]

Additionally, the earnings release, accompanying slides, and an archived webcast of this conference call will be available at the Company’s Investor Relations website at https://ir.sbc-holdings.com/

About SBC Medical Group Holdings Incorporated
SBC Medical is a Medical Services Organization providing management support across a wide range of healthcare fields, including advanced aesthetic healthcare, dermatology, orthopedics, fertility treatment, gynecology, dentistry, hair loss treatment (AGA), and ophthalmology. The Company manages a diverse portfolio of clinic brands and is actively expanding its global presence, particularly in the United States and Asia, through both direct operations and medical tourism initiatives. In September 2024, the Company was listed on Nasdaq, and in June 2025, it was selected for inclusion in the Russell 3000^® Index, a broad benchmark of the U.S. equity market. Guided by its Group Purpose “Contributing to the well-being of people around the world through medical innovation,” SBC Medical Group Holdings Incorporated continues to provide safe, trusted, and high-quality medical services while further strengthening its international reputation for quality and trust in medical care.

For more information, visit https://sbc-holdings.com
For more insights and updates from SBC Medical, follow us on LinkedIn.

Forward-Looking Statements
This press release contains forward-looking statements. Forward-looking statements are not historical facts or statements of current conditions, but instead represent only the Company’s beliefs regarding future events and performance, many of which, by their nature, are inherently uncertain and outside of the Company’s control. These forward-looking statements reflect the Company’s current views with respect to, among other things, the Company’s plans and strategies for service expansion; growth in revenue and earnings; and business prospects. In some cases, forward-looking statements can be identified by the use of words such as “may,” “should,” “expects,” “anticipates,” “contemplates,” “estimates,” “believes,” “plans,” “projected,” “predicts,” “potential,” “targets” or “hopes” or the negative of these or similar terms. The Company cautions readers not to place undue reliance upon any forward-looking statements, which are current only as of the date of this release and are subject to various risks, uncertainties, assumptions, or changes in circumstances that are difficult to predict or quantify. The forward-looking statements are based on management’s current expectations and are not guarantees of future performance. The Company does not undertake or accept any obligation to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. Factors that may cause actual results to differ materially from current expectations may emerge from time to time, and it is not possible for the Company to predict all of them; such factors include, among other things, changes in global, regional, or local economic, business, competitive, market and regulatory conditions, and those listed under the heading “Risk Factors” and elsewhere in the Company’s filings with the U.S. Securities and Exchange Commission (the “SEC”), which are accessible on the SEC’s website at www.sec.gov.

Contacts
Hikaru Fukui / Head of IR Department; E-mail: ir@sbc-holdings.com

Product mini-site presents designs for customer reporting, private AI Q&A and agentic workflows; CogniAI integration would extend document processing

KUALA LUMPUR, Malaysia, Nov. 03, 2026 (GLOBE NEWSWIRE) — BioNexus Gene Lab Corp. (Nasdaq: BGLC) (“BioNexus” or the “Company”) today introduced BGLC 1Lab, its laboratory workflow product, and announced its initial launch as a controlled GeneMatrix-focused pilot at its MRNA Scientific Sdn. Bhd. subsidiary. A dedicated product mini-site is available at www.bionexusgenelab.com/1lab.

1Lab is designed to connect clinic orders, specimen reception, bench activity, scientific review and report delivery in one traceable record. The workflow design links each step to accountable staff and makes a test’s progress and exceptions visible.

“We are in a transition phase in our healthcare business, toward services that can integrate with increasingly autonomous AI. We believe an important part of AI’s next phase of growth will come from connecting advances in large language models with the data and workflows needed to deliver useful services. We are developing 1Lab around laboratory operations, customer reporting and private AI, with qualified professionals retaining responsibility for laboratory and clinical decisions.” Sam Tan, Chief Executive Officer of BioNexus Gene Lab Corp.

Starting with GeneMatrix

BioNexus has built an enterprise version of GeneMatrix, the software behind its blood-based genomic screening, and completed internal workflow testing. The 1Lab pilot at MRNA Scientific’s laboratory in Penang, Malaysia, focuses on connecting that analysis with the surrounding operational workflow.

The pilot will evaluate traceability and staff review before wider deployment. Clinical release of GeneMatrix Enterprise remains subject to validation and applicable security, privacy, regulatory and management reviews.

Secure reporting and private AI Q&A

The reporting system is designed to give referring clinics and authorized customers secure web and mobile access to released laboratory reports. That design includes viewing and downloading the current report, clear identification of corrected versions and retention of the report history. Patient access would follow clinician review and the laboratory’s release policy.

Private AI Q&A is designed to help customers understand their own reports in plain language. The Q&A design grounds answers in the exact released report version and approved explanatory material, with supporting references and limits on questions those sources cannot answer. Clinical interpretation and follow-up remain with the clinician. Release of report Q&A remains subject to clinical review, validation and regulatory assessment.

Agentic AI under laboratory control

1Lab’s AI design starts with staff-requested assistance: reading requisitions, drafting clinic messages and retrieving approved procedures. Source checks and named-person review govern each draft. More autonomous agent workflows are a longer-term development direction; specimen acceptance, run decisions, result verification and report authorization remain with authorized staff.

1Lab’s private and sovereign AI design centers on institutional control over model operation, data processing and access. It covers local hardware and institutionally managed computing capacity. For Malaysian deployments, design requirements include domestic hosting of personal data and exclusion of laboratory and patient records from public AI services and shared-model training.

CogniAI integration

Following the anticipated closing of the previously announced Malaysian license agreement with Ruanyun Edai Technology Inc. (Nasdaq: RYET) (“Ruanyun”), BioNexus intends to integrate Ruanyun’s CogniAI document-intelligence platform into 1Lab. CogniAI would provide document recognition, classification and extraction for 1Lab’s reading agents.

The document-processing integration would support GeneMatrix report-access and companion development; report Q&A requires separate source-grounding, validation and release controls.

The October 5, 2026 license agreement with Ruanyun remains subject to technology delivery, written acceptance, due diligence and required approvals. Commercial deployment can begin only after closing.

Connecting laboratories and clinics

MarketsandMarkets estimates the worldwide laboratory information management system market, which spans all industries and includes software, services and support, at US$3.26 billion in 2026 and projects US$5.84 billion by 2031.¹ Malaysia’s Ministry of Health records 214 licensed private hospitals and 11,067 registered private medical clinics as of December 31, 2024.² BioNexus sees an opportunity to connect laboratories and referring clinics through workflow, secure reporting and private AI, starting with its own pilot.

Initial availability is limited to the controlled MRNA Scientific pilot. Release beyond the pilot, including agent, API and patient features, is subject to development, validation and applicable approvals. The mini-site includes designs shown with demonstration data. Clinics, laboratories and potential partners can explore 1Lab at www.bionexusgenelab.com/1lab or contact sales@bionexusgenelab.com.

¹ MarketsandMarkets, “Laboratory Information Management System (LIMS) Market – Global Forecast to 2031,” September 2026.

² Ministry of Health Malaysia, Health Facts 2025.

About BioNexus Gene Lab Corp.

BioNexus Gene Lab Corp. (Nasdaq: BGLC) is a technology-focused company operating across biotechnology, precision diagnostics and specialty materials. Through its subsidiaries, investments and licensing arrangements, the Company is developing new healthcare and life-science businesses alongside its established operations.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.

Forward-looking statements include the 1Lab pilot and wider release; GeneMatrix integration and validation; agentic workflows, customer reporting, private AI Q&A and related access features; private and sovereign AI deployment; CogniAI delivery, acceptance, closing and integration; the transition toward services integrating with increasingly autonomous AI; management’s view of future AI growth; industry-market projections; and adoption and commercialization beyond MRNA Scientific.

Actual results may differ materially because of development and integration difficulties; AI output errors and model or host performance; validation, cybersecurity, privacy, data-residency and healthcare regulatory requirements; technology delivery, acceptance, due diligence and closing conditions; intellectual-property and third-party rights; implementation resources and funding; competition and customer adoption; and other risks in the Company’s latest Form 10-K, subsequent Forms 10-Q and other SEC filings. Third-party market estimates have not been independently verified by the Company and are subject to differing definitions and forecasting assumptions. The pilot does not establish clinical validation or assure commercial availability, customer contracts or revenue. Forward-looking statements speak only as of the date made. BioNexus undertakes no obligation to update them except as required by law.

Investor Relations and Corporate Communications

BioNexus Gene Lab Corp.
ir@bionexusgenelab.com